Administration of Fibrinogen Concentrate for Refractory Bleeding

Summary

Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive prophylactic platelet transfusion when platelet level reaches 10x109.L-1, to avoid spontaneous major bleeding. Due to immune or nonimmune factors, platelet refractoriness may be observed and is defined as a repeated suboptimal response to platelet transfusions with lower-than-expected post-transfusion count increments. The management of patients with alloimmunization is complex and prophylactic platelet support is no longer indicated. Therefore, platelet refractoriness remains a clinically challenging complication.

Timeline

Start

2022-02-10

Primary completion

2023-05-25

Completion

2023-06-27

Outcome

Outcome not reported

Stopped: “Only one patient was included in this study due to overly restrictive inclusion and exclusion criteria.”

Drugs

Indications